Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Fractyl Health on the transaction, and Goodwin Procter advised the underwriters. Fractyl Health (Nasdaq: GUTS) announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction. Verve Therapeutics, Inc. (Nasdaq:VERV) announced the expansion of its relationship with Eli Lilly...
You must be a Standard 1 Year member to access this content.
White & Case and Wilson Sonsini Goodrich & Rosati advised Azurity Pharmaceuticals, Inc., and Kirkland & Ellis advised Slayback Pharma LLC on the transaction. Azurity Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Azurity on the deal while King & Spalding represented Arbor Pharmaceuticals. Azurity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter advised Graphite Bio on the deal. Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
You must be a Standard 1 Year member to access this content.
